John J Lyons

US Patent:

6977247, Dec 20, 2005

Filed:

Feb 21, 2002

Appl. No.:

10/081974

Inventors:

Joseph Rubinfeld - Danville CA, US
Karl L. Mettinger - Berkeley CA, US
John Lyons - Moraga CA, US
Lawrence A. Romel - Oakland CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A01N043/04
A01N043/42
A61K031/70
A61K031/44

US Classification:

514 50, 514 34, 514 49, 514256, 514283

Abstract:

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

US Patent:

6998391, Feb 14, 2006

Filed:

Jul 26, 2002

Appl. No.:

10/206854

Inventors:

John Lyons - Moraga CA, US
Joseph Rubinfeld - Danville CA, US

Assignee:

SuperGen.Inc. - Dublin CA

International Classification:

A61K 31/7072

US Classification:

514 49, 514 85, 514269, 5142345, 514300, 536 235, 536 231, 435 691, 435325, 530350, 424 45, 424450

Abstract:

Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Ab1 family.

US Patent:

7307071, Dec 11, 2007

Filed:

Dec 3, 2002

Appl. No.:

10/308721

Inventors:

John F. Lyons - Moraga CA, US
Gideon Bollag - Hercules CA, US

Assignee:

Onyx Pharmaceuticals, Inc - Emeryville CA

International Classification:

A61K 31/025
A61K 31/03
A61K 31/13
A61K 31/075
A61K 31/08
A61K 31/17
A61K 31/33

US Classification:

514183, 514588, 514591, 514596, 514597, 514619, 514620, 514647, 514660, 514670, 514672, 514673, 514716, 514717, 514718, 514719, 514721, 514722, 514747, 514749, 514751

Abstract:

Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

US Patent:

7778904, Aug 17, 2010

Filed:

Nov 29, 2005

Appl. No.:

11/288557

Inventors:

John E. Lyons - Omaha NE, US

International Classification:

G06Q 40/00

US Classification:

705 35, 705 38

Abstract:

The present invention is a method for providing a low cost source of mortgage funding to sub-prime borrowers which reduces the desire of quality sub-prime borrowers to leave the mortgage pool. A lender may receive an amount of money from a financial institution in the form of a borrowing instrument. A lender may deliver an amount of money in the form of a collateralization loan to a housing agency. Housing agency may invest loan in one or more financial products, such as lender underwritten insurance policies. Housing agency may deliver individual mortgage loan recommendations to lender. Lender may borrow funds used in the collateralization loan by selling the interest bearing borrowing instrument to a financial institution. Lender may also sell individual mortgage loans to one or more government sponsored entities. From these financial products, borrowing instruments, and individual mortgages, mortgage funding may be provided to sub-prime borrowers.

US Patent:

20030147813, Aug 7, 2003

Filed:

Feb 7, 2002

Appl. No.:

10/071849

Inventors:

John Lyons - Moraga CA, US

International Classification:

A61K031/7072
A61L009/04
A61K009/127

US Classification:

424/045000, 514/049000, 424/450000

Abstract:

Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.

US Patent:

20050209186, Sep 22, 2005

Filed:

Dec 3, 2004

Appl. No.:

11/004665

Inventors:

John Lyons - Moraga CA, US

International Classification:

A61K031/7072

US Classification:

514049000

Abstract:

Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.

US Patent:

20060052334, Mar 9, 2006

Filed:

Sep 23, 2005

Appl. No.:

11/234865

Inventors:

Joseph Rubinfeld - Danville CA, US
Karl Mettinger - Berkeley CA, US
John Lyons - Moraga CA, US
Lawrence Romel - Oakland CA, US

International Classification:

A61K 31/7072
A61K 31/513
A61K 31/4745

US Classification:

514050000, 514269000, 514283000

Abstract:

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

US Patent:

20060140947, Jun 29, 2006

Filed:

Jul 13, 2005

Appl. No.:

11/181368

Inventors:

John Lyons - Moraga CA, US
Joseph Rubinfeld - Danville CA, US

International Classification:

A61K 48/00
A61K 31/7072
A61K 38/54
A61K 39/395

US Classification:

424145100, 514049000, 514044000

Abstract:

Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.